ALOPM — Oncodesign Precision Medicine Opm SA Income Statement
0.000.00%
Last trade - 00:00- €6.90m
- €5.11m
- €1.07m
Annual income statement for Oncodesign Precision Medicine Opm SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 4.41 | 3.83 | 7.98 | 1.07 |
| Cost of Revenue | ||||
| Gross Profit | 4.5 | 3.92 | 8.01 | 1.4 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 5.81 | 7.56 | 9.59 | 11 |
| Operating Profit | -1.4 | -3.73 | -1.61 | -9.94 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -1.69 | -4.08 | -1.72 | -9.85 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.154 | -2.94 | -0.231 | -8.09 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.154 | -2.94 | -0.231 | -8.09 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.154 | -2.94 | -0.231 | -8.09 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.454 | -0.43 | -0.014 | -0.487 |